Sugi Predict

Sugi Predict / Compounds / SCHEMBL9910116

SCHEMBL9910116

SCHEMBL9910116

CC(NC(=O)OC(C)(C)C)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 3/20 0.58
▸ PRMT5 O14744 1/20 0.45
▸ WDR77 Q9BQA1 1/20 0.45
▸ TP53 P04637 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ BACE1 P56817 1/20 0.38
▸ BACE2 Q9Y5Z0 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.37
▸ HIF1A Q16665 1/20 0.36
▸ DGAT1 O75907 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ TRPA1 O75762 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22664668 1.00 AAK1 (0.58) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL2696818 1.00 AAK1 (0.58) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL29533401 1.00 AAK1 (0.58) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL16813062 0.90 AAK1 (0.52) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL22664660 0.90 AAK1 (0.52) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL29418593 0.90 AAK1 (0.52) AAK1PRMT5WDR77TP53SMN1; SMN2
SCHEMBL6185324 0.87 AAK1 (0.48) AAK1PRMT5WDR77BACE1BACE2
SCHEMBL21421824 0.87 AAK1 (0.48) AAK1PRMT5WDR77BACE1BACE2
SCHEMBL9947755 0.87 AAK1 (0.48) AAK1PRMT5WDR77BACE1BACE2
SCHEMBL30578932 0.87 AAK1 (0.48) AAK1PRMT5WDR77BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 — — EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 — — EP disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 — — US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 — — US disclosed
US-8524900-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2013-09-03 — — US disclosed
US-8524900-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2013-09-03 — — US disclosed
EP-2578583-A1 Fused heterocyclic derivatives and methods of use Amgen Inc. (US) 2013-04-10 — — EP disclosed
US-8217177-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2012-07-10 — — US disclosed
US-8217177-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2012-07-10 — — US disclosed
US-8212041-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2012-07-03 — — US disclosed
US-8198448-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2012-06-12 — — US disclosed
US-8198448-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2012-06-12 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318436-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET AAK1 4656/4885PRMT5 1856/4885WDR77 4619/4885
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET AAK1 4656/4885PRMT5 1856/4885WDR77 4619/4885
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET AAK1 4656/4885PRMT5 1856/4885WDR77 4619/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET AAK1 4656/4885PRMT5 1856/4885WDR77 4619/4885
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET AAK1 4656/4885PRMT5 1856/4885WDR77 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.